(Q34069142)

30 July 2017

1 reference

title

Review of select transplant subpopulations at high risk of failure from standard immunosuppressive therapy (English)

1 reference

30 July 2017

Deierhoi MH

1

1 reference

30 July 2017

Haug M 3rd

series ordinal

2

1 reference

30 July 2017

publication date

1 October 2000

1 reference

30 July 2017

published in

Clinical Transplantation

1 reference

30 July 2017

volume

14

1 reference

30 July 2017

issue

5

1 reference

30 July 2017

page(s)

439-448

1 reference

Improved cadaveric renal transplant outcome in children

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

Children are different: the challenges of pediatric renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

Steady improvement in renal allograft survival among North American children: a five year appraisal by the North American Pediatric Renal Transplant Cooperative Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

The 1994 annual report of the North American Pediatric Renal Transplant Cooperative Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

Cyclosporin pharmacokinetics in paediatric transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

Pharmacokinetics of an oral solution of the microemulsion formulation of cyclosporine in maintenance pediatric liver transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

The pediatric nephrologist's dilemma: growth after renal transplantation and its interaction with age as a possible immunologic variable

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

Pediatric renal transplantation under tacrolimus-based immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

OKT3 induction therapy and cadaveric renal transplantation in black patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

Single center analysis of mycophenolate mofetil and Neoral/prednisone therapy for prophylaxis of rejection in African-American and Caucasian transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

Racial variation in dosage requirements of tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

Tacrolimus dosing requirements in diabetic and nondiabetic patients calculated from pretransplantation data

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

Growth after renal transplantation: correlation with immunosuppressive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

Diabetes mellitus after renal transplantation in the cyclosporine era--an analysis of risk factors

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

Risk factors for chronic rejection in pediatric renal allograft recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

Pharmacokinetics of cyclosporine after renal transplant in children

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

Experience with FK506 in living-related liver transplantation.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

Absorption characteristics of a microemulsion formulation of cyclosporine in de novo pediatric liver transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

Growth following renal transplantation in children

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

Comparison of FK-506 and cyclosporine regimens in pediatric renal transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506)

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

Inferior outcome of two-haplotype matched renal transplants in blacks: role of early rejection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

The adverse impact of high cyclosporine. Clearance rates on the incidences of acute rejection and graft loss

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

Trends in kidney transplantation in the United States

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

The effects of pravastatin on hyperlipidemia in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

Reversal of cyclosporine malabsorption in diabetic recipients of simultaneous pancreas and kidney transplant using a microemulsion formulation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

Commentary on a comparison of tacrolimus and cyclosporine for immunosuppression after cadaveric renal transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

Altered pharmacokinetics of cyclosporin in heart-lung transplant recipients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

Clinical use and bioavailability of tacrolimus in heart-lung and double lung transplant recipients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

Improved absorption and bioavailability of cyclosporine A from a microemulsion formulation in lung transplant recipients affected with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

An investigation of the pharmacokinetics, toxicity, and clinical efficacy of Neoral cyclosporin in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

The outcome of pregnancy following renal transplantation--the experience of a single center

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

Pregnancy outcomes in female renal transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

Drug safety issues in pregnancy following transplantation and immunosuppression: effects and outcomes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2000.140501.X

7 January 2021

10.1034/J.1399-0012.2000.140501.X

Identifiers

DOI

1 reference

30 July 2017

1 reference